Cite

HARVARD Citation

    Reardon, D. et al. (n.d.). CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-oncology. p. ii40. [Online]. 
  
Back to record